INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0104
hours per response:			0.5

1. Name and Address of Reporting Person^*

Monteil Clement

(Last)

(First)

(Middle)

C/O VIRAX BIOLABS, BIOCITY GLASGOW

BO'NESS RD, NEWHOUSE

(Street)

LANARKSHIRE

ML1 5UH

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/05/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

**Table II - Derivative Securities Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options	⁽¹⁾	12/07/2032	Ordinary Shares	60	310	D
Stock Options	⁽²⁾	04/18/2033	Ordinary Shares	400	150	D
Stock Options	⁽³⁾	04/18/2034	Ordinary Shares	800	17	D
Stock Options	⁽⁴⁾	04/08/2035	Ordinary Shares	600	21.9	D
Stock Options	⁽⁵⁾	04/08/2036	Ordinary Shares	3,000	3.75	D

Explanation of Responses:

1. On December 7, 2022, the Company granted 60 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on December 7 of each of 2023, 2024 and 2025. The vested portions of such options will become exercisable upon vesting.

2. On April 18, 2023, the Company granted 400 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.

3. On April 18, 2024, the Company granted 800 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 600 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

5. On April 8, 2026, the Company granted 3,000 stock options under the Company's 2026 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2027, 2028 and 2029. The vested portions of such options will become exercisable upon vesting.

	/s/ Clement Monteil	10/20/2026
	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.